Tiapamil
Tiapamil (INN; also known as dimeditiapramine) is a calcium antagonist or calcium channel blocker.[1][2] It is an experimental drug that has never been marketed.[3]
Tiapamil has been described as an antianginal agent. It exhibits properties of anti-arrhythmic medications. These are medications that are used to treat unusually fast or irregular heartbeats. Examples of arrhytmthic conditions include atrial fibrillation, atrial flutter, and super-ventricular tachycardia.[4] Upon research, the drug shows promising effects on treatment of these condition. Research seeks to create a treatment with tiapamil in order to mitigate the side effects of the more commonly prescribed calcium antagonist and anti-hypertensive verapamil. The two drugs have similar properties; however, tiapamil appears to treat arrhythmic conditions without many of the hypotensive, negative inotropic, and negative chronotropic side effects. Tiapamil is a calcium channel blocker that acts on the slow calcium channels. It can treat ventricular arrhythmias to a higher degree than traditional calcium antagonists.[medical citation needed]
See also
References
- ^ Cocco G, Strozzi C, Chu D (June 1979). "Human electropharmacology of the calcium antagonist dimeditiapramine (Ro 11-1781) in coronary patients". Clinical Cardiology. 2 (3): 212–216. doi:10.1002/clc.4960020307. PMID 509799. S2CID 24609271.
- ^ Nowak FG, Cocco G, Chu D, Gasser DF (December 1980). "Antiarrhythmic effect of the calcium antagonist tiapamil (Ro 11-1781) by intravenous administration in patients with coronary heart disease". Clinical Cardiology. 3 (6): 371–376. doi:10.1002/clc.4960030603. PMID 6161729. S2CID 196402596.
- ^ "Tiapamil". AdisInsight. Springer Nature Switzerland AG.
- ^ Cocco G, Chu D, Strozzi C (April 1979). "Dimeditiapramine (Ro 11-1781), a new calcium antagonist, in the management of supraventricular tachyarrhythmias in patients with acute myocardial infarction". Clinical Cardiology. 2 (2): 131–134. doi:10.1002/clc.4960020208. PMID 262567. S2CID 38589956.